Merz Aesthetics' Belotero Balance (+) has received approval from the U.S. Food and Drug Administration (FDA) for the enhancement of the infraorbital hollow (under-eye volume loss) in adults who are 21 years and older.
With the latest FDA approval of injections at the infraorbital hollowing, patients may achieve a more youthful look, free from noticeable dark circles, hollow areas, and wrinkles under the eyes, through the use of Belotero injections in the tear-trough and nearby regions.
The approval is a result of the successful pivotal study conducted in June 2023, which showed the effectiveness and safety of using Belotero Balance (+) for treating infraorbital hollows.
“Infraorbital hollowing that often occurs naturally in younger people or with aging can impact a person’s confidence, which is why patients seek medical aesthetics treatment to improve the appearance of this area of the face,” said Brian S. Biesman, M.D. F.A.C.S.
“I have countless patients coming to me with concerns about under-eye volume loss,” adds Dr. Daniel Campos, DNP, APRN Board-Certified specializing in non-surgical aesthetic and anti-aging treatments in Miami, Florida. “To be able to offer a safe and effective treatment from the Merz Aesthetics portfolio is an exciting advancement, and one I’m very much looking forward to bringing to my practice.”
Belotero Balance (+) is indicated for injection into the mid-to-deep dermis for correction of moderate-severe facial wrinkles and folds, such as nasolabial folds and perioral lines, and injection into the infraorbital hollows.
First approved in 2011, Belotero Balance® is a hyaluronic acid (HA) filler that provides a smooth, all-around refinement for filler patients. Belotero Balance® (+) offers the same benefits plus the advantages of a lidocaine formulation.